PTC Therapeutics (NASDAQ:PTCT) Given New $53.00 Price Target at JPMorgan Chase & Co.

PTC Therapeutics (NASDAQ:PTCT – Free Report) had its target price hoisted by JPMorgan Chase & Co. from $43.00 to $53.00 in a research report released on Tuesday morning, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other brokerages also recently weighed in on PTCT. Cantor Fitzgerald reissued […]

Related Keywords

Texas ,United States ,Jeromeb Zeldis ,Raymond James ,Matthewb Klein ,Jpmorgan Chase Co ,Jefferies Financial Group ,Hexagon Capital Partners ,Therapeutics Company Profile ,Morgan Stanley ,Therapeutics Inc ,Allspring Global Investments Holdings ,Cantor Fitzgerald ,Goldman Sachs Group ,Free Report ,Get Free Report ,Director Jerome ,Capital Partners ,Global Investments Holdings ,Retirement System ,Rhumbline Advisers ,